The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis
MASH cirrhosis is characterized by a broad spectrum of hepatic impairment and portal-systemic shunting. DSI, SHUNT%, and RISK ACE may provide early estimates of potential clinical benefit with resmetirom treatment. MAESTRO-NAFLD-1 was registered at ClinicalTrials.gov (NCT04197479).
Authors
- Joanne C. Imperial
- John Kittelson (ORCID: https://orcid.org/0000-0002-4929-1414)
- Michael P. McRae (ORCID: https://orcid.org/0000-0002-2126-9442)
- Naim Alkhouri (ORCID: https://orcid.org/0000-0001-9872-2391)
- Gregory T. Everson (ORCID: https://orcid.org/0000-0003-0454-3566)
- Brandon Hill (ORCID: https://orcid.org/0000-0001-6509-9302)
- Sam E. Moussa
- Rebecca Taub
Institutions
- Custom Electronics (United States) (US)
- Banner - University Medical Center Tucson (US)
- Madrigal Pharmaceuticals (United States) (US)
- ColdQuanta, Inc., DBA Infleqtion (United States) (US)
- Arizona Liver Health (US)
Publication Details
- Journal
- Gastro Hep Advances
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.gastha.2025.100785
- Citations
- 1
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Madrigal Pharmaceuticals